Citius Oncology Soars 12.34% on Expanded Lymphir Distribution

Citius Oncology's stock surged 12.34% in pre-market trading on July 16, 2025, driven by significant developments in its distribution network.

Citius Oncology has expanded its distribution network for Lymphir, its FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma. The company executed a distribution services agreement with Cencora, a global pharmaceutical services company. This partnership will enhance the availability of Lymphir across Cencora's extensive distribution network, marking a crucial step in Citius Oncology's commercial launch strategy.

Despite securing FDA approval for Lymphir, Citius Oncology has faced delays in commercialization, with the launch now anticipated for late 2025. The new distribution agreement with Cencora is expected to mitigate these delays by broadening the reach of Lymphir, potentially boosting investor confidence and driving stock performance.